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ABSTRACT
Purpose To demonstrate drug/polymer nanoparticles can
increase the rate and extent of oral absorption of a low-
solubility, high-permeability drug.
Methods Amorphous drug/polymer nanoparticles containing
celecoxib were prepared using ethyl cellulose and either sodium
caseinate or bile salt. Nanoparticles were characterized using
dynamic light scattering, transmission and scanning electron
microscopy, and differential scanning calorimetry. Drug release
and resuspension studies were performed using high-
performance liquid chromatography. Pharmacokinetic studies
were performed in dogs and humans.
Results A physical model is presented describing the nano-
particle state of matter and release performance. Nanoparticles
dosed orally in aqueous suspensions provided higher systemic
exposure and faster attainment of peak plasma concentrations
than commercial capsules, with median time to maximum drug
concentration (Tmax) of 0.75 h in humans for nanoparticles vs.
3 h for commercial capsules. Nanoparticles released celecoxib
rapidly and provided higher dissolved-drug concentrations than
micronized crystalline drug. Nanoparticle suspensions are
stable for several days and can be spray-dried to form dry
powders that resuspend in water.
Conclusions Drug/polymer nanoparticles are well suited for
providing rapid oral absorption and increased bioavailability of
BCS Class II drugs.
KEY WORDS bioavailability.celecoxib.ethylcellulose.
nanoparticles.rapidabsorption
INTRODUCTION
Recent reports estimate that at least 40% of new drug
candidates are poorly soluble in water, resulting in low
bioavailability (1–3). The oral absorption of low-solubility,
high-permeability BCS Class II compounds, in particular, is
often limited (4,5). Many of these compounds require
solubilization technologies to achieve the desired extent
and rate of oral absorption.
A number of delivery systems have been pursued to
increase the oral bioavailability of these compounds through
increased dissolution rate and/or increased dissolved-drug
levels. These approaches include nanocrystals (6,7); inclusion
complexes, such as cyclodextrins (8); and solution- or
emulsion-based formulations (2,9). While some of these
technologies have shown promise for oral delivery of low-
solubility compounds, each technology has its limitations.
For example, inclusion complexes can effectively solubi-
lize drugs that fit well into the cavity of the carrier, which is
typically hydrophobic. Binding is drug-specific, and the
modest binding constants for most drugs limit the increase
in solubilized drug levels relative to crystalline solubility (8).
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and more rapid release, but can pose greater challenges
with respect to low drug loading and physical and chemical
stability compared with solid forms (3). Nanocrystals have
the potential to increase bioavailability of dissolution-
limited drugs by increasing the surface area, and therefore
the dissolution rate, of low-solubility drug crystals (7,10,11).
In situations where increasing the dissolution rate is not
sufficient to adequately increase bioavailability, amorphous
drug forms that can provide dissolved-drug levels higher
than crystalline solubility can be advantageous. The drug/
polymer nanoparticles described here are complementary
to other bioavailability-enhancing technologies and possess
favorable characteristics that may position them to be
enabling for applications where rapid dissolution and/or
increased dissolved-drug levels are required.
In general, solid amorphous dispersions can provide high
bioavailability for low-solubility drugs, while being readily
incorporated into solid dosage forms (12–14). Although
such dispersions can provide rapid absorption, the rate
of absorption depends on a number of dispersion
properties, including drug loading and the nature of
the dispersion matrix material. High-surface-area dis-
persions, such as the drug/polymer nanoparticles de-
scribed here, are particularly well suited to rapid-onset
applications due to their rapid release rate (15). In
addition, these nanoparticles, like other amorphous dis-
persions, can provide dissolved-drug concentrations higher
than crystalline solubility, which contribute to faster
absorption rates and higher total absorption (16).
This paper demonstrates the feasibility of using a drug/
polymer nanoparticle dispersion to improve the oral
bioavailability and achieve rapid absorption of a model
BCS Class II compound, celecoxib. The preparation,
characterization, and in vivo performance of the nano-
particles in canine and human clinical trials are described.
Celecoxib is a cyclooxygenase-2 (COX-2) inhibitor used
in the treatment of osteoarthritis and rheumatoid arthritis
(17) and has been used in anticancer therapy (18). Several
solid-state forms of celecoxib have been investigated (19),
and celecoxib is marketed commercially as capsules
containing crystalline drug. While these capsules have
shown acceptable systemic exposure in humans,
1 solubi-
lized formulations offer the potential to provide increased
bioavailability, and therefore a reduced dose. In addition,
such formulations may be absorbed rapidly, reaching
effective blood levels more quickly and providing faster
onset of pain relief. Rapid dissolution rates have been
achieved using an emulsion-diffusion nanoparticle system
(20). Celecoxib proniosomes have also been produced and
provided an approximately 20% increase in bioavailability,
but a significantly longer time to maximum plasma drug
concentration (Tmax) relative to the commercial capsule in
humans (21).
The data presented here support the use of amorphous
drug/polymer nanoparticles as a promising formulation
approach for oral delivery of celecoxib and other BCS Class
II compounds, particularly when rapid absorption is desired.
MATERIALS AND METHODS
Materials
Bulk crystalline celecoxib and 200-mg commercial capsules
of celecoxib (Celebrex
®) were obtained from Pfizer Inc.
(Groton, CT). Ethyl cellulose (Ethocel
® Viscosity 4) was a
generous gift from the Dow Chemical Co. (Midland MI).
Sodium taurocholate (NaTC) was purchased from Sigma
Aldrich (St. Louis, MO). 1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) was purchased from Avanti Polar
Lipids Inc. (Alabaster, AL). Sodium chloride (NaCl) was
purchased from VWR (Radnor, PA). Disodium hydrogen
phosphate (Na2HPO4) and potassium dihydrogen phosphate
(KH2PO4) were purchased from Sigma Aldrich, and
potassium chloride (KCl) was purchased from Fisher
Scientific (Pittsburgh, PA). The –L grade of hydroxypropyl
methyl cellulose acetate succinate (HPMCAS-L) was
obtained from Shin-Etsu Chemical Co. Ltd. (Tokyo, Japan).
β-Casein was obtained from Sigma Chemicals (St. Louis,
MO). Sodium β-caseinate was formed by adding 400 mg of
β-casein to 80 mL of deionized water and then adding
NaOH solution to achieve a pH of 7.0. The solution was
lyophilized to obtain solid sodium β-caseinate, which is
referred to as “casein” below for brevity.
The model fasted duodenal solution (MFDS) consisted of
7.3 mM NaTC, 1.4 mM POPC, 82.1 mM NaCl, 20 mM
Na2HPO4, and 46.7 mM KH2PO4, which was adjusted to
pH 6.5 with NaOH and then to 290 mOsm using 1:20.4
NaCl:KCl.
Syringe filters (1-μm glass microfiber and 0.45-μm
Supor
® polyethersulfone membrane filters) were purchased
from Pall Corp. (Port Washington, NY). Molecular-weight-
cutoff (MWCO) filters (100 kDa, Microcon Ultracel YM-
100) were purchased from Millipore Corp. (Billerica, MA).
Preparation of Nanoparticle Formulations
Nanoparticle Suspensions for In Vitro Characterization
Nanoparticle suspensions were prepared for in vitro dissolu-
tion testing and free-drug (dissolved drug plus drug in bile-
1 To our knowledge, no absolute bioavailability has been reported for
the commercial capsule in humans, but the bioavailability of celecoxib
has been reported to be 22% to 40% in dogs (17).
428 Morgen et al.salt micelles) measurement using the following method.
Bulk crystals of celecoxib and solid ethyl cellulose were
dissolved in approximately 8 g of methylene chloride.
Formulations were prepared at four drug/polymer ratios—
1:9, 1:3, 1:1, and 3:1—each at a total solids concentration
of 15 mg/g solids in methylene chloride. Approximately
14 mg of NaTC was dissolved in 20 mL of water. The
methylene chloride solution containing dissolved polymer
and drug was mixed with the NaTC solution using a
Polytron 3100 rotor stator (Kinematica Inc., Bohemia, NY)
at 10,000 rpm for 5 min. This coarse emulsion was then
further emulsified using a Microfluidizer M110S fluids
processor (Microfluidics, Newton, MA) fitted with Z-shaped
interaction chamber with a 100-μm-diameter channel and
operated at 12,500 psi for 5 min. The emulsion was then
placed on a rotoevaporator, and the methylene chloride
was removed under reduced pressure at approximately
25°C for approximately 20 min.
Spray-Dried Nanoparticles for In Vitro Dissolution Experiments
Spray-dried nanoparticles were prepared from an aqueous
nanoparticle suspension prepared using the emulsification
technique described above. Two solutions were used to
prepare the suspension: 14.4 g celecoxib and 14.4 g ethyl
cellulose in 138.6 g ethyl acetate and 9.6 g casein in 461.5 g
water using an Avestin C55 homogenizer (Avestin Inc.,
Ottawa, Ontario, Canada).
Spray-dried nanoparticles were prepared from this
suspension using a Niro Mobile Minor™ spray-dryer
(GEA Niro, Søborg Denmark). The suspension was
pumped at about 20 g/min using a high-pressure pump
to the spray-dryer, which was equipped with a Schlick No.
1.0 pressure nozzle (Dusen Schlick GmbH, Untersiemau,
Germany) and a 9-inch chamber extension to increase the
vertical height of the dryer. Nitrogen drying gas was
introduced at 1,900 g/min and an inlet temperature of
90°C, and the evaporated solvent and drying gas exited the
spray-dryer at an outlet temperature of 50°C. The solid
powder was collected in a cyclone. The powder composi-
tion had a mass ratio of 37.5:37.5:25 celecoxib:ethyl
cellulose:casein.
Nanoparticle Suspensions for Dog Studies
Nanoparticle suspensions were prepared for dog pharma-
cokinetic studies from two solutions: 1.375 g of celecoxib
and 1.375 g ethyl cellulose dissolved in 50 mL methylene
chloride and 917 mg casein dissolved in 200 mL of water.
The two solutions were mixed using a rotor stator for
3 min at 10,000 rpm. The coarse emulsion was then
emulsified further using an M-110S Microfluidizer at
12,500 psi for 20 min. Methylene chloride was then
removed by rotoevaporation for 15 min. Two such
batches were made and mixed. The potency of celecoxib
was measured using high-performance liquid chromatog-
raphy (HPLC), and the suspension was diluted to 5 mg
active (mgA)/mL.
Nanoparticle Oral Powder for Constitution (OPC) for Dog
Studies
A nanoparticle OPC was prepared for the same dog
pharmacokinetic studies by preparing a similar emulsion
at higher concentration (80 mg/mL solids). This emulsion
was then spray-dried using a Mobile Minor spray-dryer
using an inlet temperature of 80°C, an outlet temperature
of 50°C, and a flow rate of 20 g/min. The resulting OPC
was dried at ambient temperature under reduced pressure
in a vacuum desiccator for approximately 18 h to remove
residual solvent.
Spray-Dried Nanoparticles for Clinical Studies
For the clinical studies, nanoparticles were made by
dissolving 8.62% celecoxib (w/w) and 8.62% (w/w) ethyl
cellulose in ethyl acetate. An aqueous solution of 2% casein
(w/w) in water was prepared. The solutions were mixed in
a stainless-steel tank using a Bematek rotor stator at
3600 rpm for 20 min (Bematek Systems Inc., Salem, MA).
The mixture was then emulsified by 20 passes through an
Avestin C55 homogenizer at 12,500 psi. Solvent was
removed under vacuum at 40°C.
The resulting aqueous nanoparticle suspension was
pumped at about 24 g/min using a high-pressure pump
to the Mobile Minor spray-dryer equipped as described
above. A high-pressure pump was used to deliver liquid to
the nozzle. Drying gas (i.e., nitrogen) at a flow rate of
1,850 g/min was circulated at an inlet temperature of
100°C, and the evaporated solvent and drying gas exited
the spray-dryer at a temperature of 50°C. The resulting
solid powder, which was collected in a cyclone, had a
mass ratio of 37.5:37.5:25 celecoxib:ethyl cellulose:casein.
This powder was used for imaging using scanning electron
microscopy (SEM) analysis, powder x-ray diffraction
(PXRD) analysis, and the resuspension studies described
below.
Spray-Dried Dispersion (SDD) for Clinical Studies
A 50:50 celecoxib:HPMCAS-L SDD was prepared for
clinical studies using the Mobile Minor spray-dryer
described above. Celecoxib and HPMCAS-L were dissolved
at 5 wt% solids each in methanol, yielding a solution with a
total solids content of 10 wt%. The solution was prepared in a
stainless-steel tank equipped with a top-mounted mixer. In a
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methanol was added to the tank, and 2 kg of celecoxib was
then added. The mixture was stirred for 30 min at room
temperature until the drug was dissolved. Two kilograms of
HPMCAS-L was added and stirred for 1 h.
The resulting methanol solution was pumped at about
60 g/min using a high-pressure pump to the Mobile
Minor spray-dryer. Drying nitrogen gas was introduced at
1,900 g/min and an inlet temperature of 110°C, and the
evaporated solvent and drying gas exited the spray-dryer
at 55°C. The resulting SDD powder, which was collected
in a cyclone, had a mass ratio of 50:50 celecoxib:
HPMCAS-L.
The SDD was placed in a tray-dryer for secondary
drying at controlled temperature and humidity to remove
residual methanol to a target level of<0.05 wt%. The SDD
was spread out in a tray to a bed depth of no more than
1 in. and held at 40°C/15% relative humidity (RH) for a
minimum of 3 h.
Particle Sizing
Nanoparticle size was measured by dynamic light scattering
(DLS) using a BI-200SM particle size analyzer with a BI-
9000AT correlator (Brookhaven Instruments Inc., Holtsville,
NY).Particlesizeisreportedasthediameterdeterminedusing
the cumulant cubic fitting algorithm.
Nanoparticle morphology and size heterogeneity was
assessed using cryogenic transmission electron microscopy
(cryo-TEM). The suspensions were sampled and prepared
f o rc r y o - T E Ma n a l y s i so na nF E IV i t r o b o t ™ (FEI
Company, Hillsboro, OR) using the following method. A
10-μL sample of suspension was applied to a Lacey Carbon
TEM grid in the Vitrobot chamber equilibrated to 90%
R H .T h eg r i dw a sb l o t t e do n c ef o r2sa n dt h e n
immediately plunged into freezing liquid ethane. The grid
was transferred to a Taylor-Wharton liquid-nitrogen
storage dewar and stored until imaging could be per-
formed. Imaging was carried out at 200 kV (using a
thermionic LaB6 electron source) in an FEI Tecnai20
Sphera TEM instrument using a Gatan Model 626
cryogenic holder (Gatan Inc., Pleasanton, CA) and low-
dose imaging mode facilitated by the FEI Tecnai User
Interface. The TEM was equipped with a Gatan Multiscan
CCD Model 794 camera, and images were captured using
a Gatan digital micrograph.
For SEM imaging, the spray-dried nanoparticle powders
were spread on a post using double-sided tape. They were
then sputter-coated with Au/Pd using an Anatech Hummer
6.2 sputter system for approximately 8 min at 7 V and 15
to 20 mA. They were then imaged on a Hitachi S-3400 N
SEM instrument (Hitachi High Technologies America Inc.,
Schaumburg, IL).
HPLC Analysis
Aqueous drug-containing samples were analyzed using a
Hewlett Packard Series 1100 HPLC instrument (Hewlett
Packard Development Corp., Palo Alto, CA) with an
Agilent Zorbax SB-C8 column (3.5 μm, 75 mm×4.6 mm)
with an injection volume of 10 μL, column temperature of
25°C, and flow rate of 1.5 mL/min with ultraviolet (UV)
detection at 254 nm. Celecoxib had a retention time of
approximately 4 min using an isocratic method with 55:44
acetonitrile:10 mM ammonium acetate.
Thermal Analysis
The glass-transition temperature (Tg)o fc a s e i n ,e t h y l
cellulose, celecoxib, and the drug/polymer nanoparticles
was obtained by modulated differential scanning calorimetry
(mDSC) using a TA Q-1000 differential scanning
calorimeter (TA Instruments, New Castle, DE). Ther-
mograms were analyzed using TA Instruments software.
Polarized Light Microscopy (PLM)
The nanoparticle suspensions were examined for the
presence of crystals using PLM. A Nikon E600 microscope
was used at 200- to 400-fold magnification.
PXRD
Spray-dried nanoparticle powders were analyzed by PXRD
using a Bruker AXS diffractometer. Approximately 10 to
20 mg of powder was placed in a zero-background-holder
sample cup with single-crystal silicon sample surfaces. The
sample cup was spun in the horizontal plane while the
goniometer was stepped through a 2Θ angle of 4° to 40°
with a 0.01° step size at a rate of 1 s/step.
Solubility Testing
Celecoxib solubility was measured in water and in MFDS
by placing excess bulk crystalline drug in an aqueous
medium and stirring overnight at room temperature. A
portion of the supernatant was placed in a microcentrifuge
tube and centrifuged at 12,000 rpm for 5 min before it was
analyzed by HPLC.
Release Testing
Nonsink release testing of suspensions containing the drug/
polymer nanoparticles or bulk crystalline drug was per-
formed as a function of drug loading in the particle. Drug/
polymer nanoparticles were manufactured as described
above at solids contents of approximately 6 mg/mL. Each
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active (μgA)/mL in MFDS, placed in a glass scintillation
vial, and stirred at 60 rpm using a magnetic stir bar. At
each time point, duplicate 500-μL aliquots were removed
from the vial, placed into microcentrifuge tubes fitted with
100-kDa MWCO filters, and spun at 12,000 rpm for
5 min. After spinning, 100 μLo ft h ef i l t r a t ew a sm i x e d
with 500 μL of dimethylsulfoxide (DMSO) and analyzed
by HPLC.
Resuspension Testing of Spray-Dried Nanoparticle
Powders
The resuspendability of spray-dried nanoparticle powders
was assessed using a “gastric transfer” release test. For this
test, 267 mg of spray-dried 37.5:37.5:25 celecoxib:ethyl
cellulose: casein nanoparticle powder was placed in 5 mL
of water. The resulting suspension was then added to
45 mL of 0.1 N HCl to form a suspension containing
2 mgA/mL celecoxib. This simulated gastric suspension
(pH ~1.2) was stirred at 100 rpm. Aliquots of 0.75 mL
were removed 5, 15, and 35 min after the suspension was
prepared.
At 35 min, the suspension was diluted with 50 mL of a
pH 6.5 phosphate-buffered saline (PBS) solution. The pH
of the diluted suspension was 6.5. After dilution with the
PBS solution, additional aliquots were taken at 1, 3, 5,
10, 30, and 60 min. All aliquots were assayed for
celecoxib in three different ways: with no filtering, after
f i l t e r i n gt h r o u g ha1 - μm syringe filter, and after filtering
through a 1-μm syringe filter and a 0.45-μms y r i n g e
filter. The goal was to assess if the spray-dried powder
was likely to resuspend to re-form nanoparticles without
aggregation when dosed orally as a solid.
Pharmacokinetic Studies in Dogs
The pharmacokinetics of celecoxib nanoparticles and
commercial celecoxib capsules were evaluated in a fasted
dog model. In the nanoparticle study, performed at
Covance Labs Inc. (Princeton, NJ), six male beagle dogs
were each given a 20-mgA/kg dose of celecoxib nano-
particles. The animals were fasted overnight (at least 8 h
before dosing through approximately 12 h after dosing).
Individual doses were calculated based on body weights
taken on the day each dose was administered.
To determine if drying and resuspending the nano-
particles affected in vivo performance, the nanoparticles
were dosed as an OPC and as a suspension. In the first leg
of the study, the OPC was tested. Spray-dried celecoxib
nanoparticles (described above) were resuspended on the
day of dosing. A stir bar was added to a bottle
containing the spray-dried formulation (2000 mg), and
approximately 400 mL of deionized water was added to
the bottle. This produced a milky white suspension
having a final concentration of 5 mg/mL. The final dosing
suspension was administered to dogs via oral gavage with a
dosing volume of 4 mL/kg.
In the second leg of the study, the same 5-mg/mL
formulation was prepared as described above and
refrigerated as a liquid suspension until dosing. The
formulation was a uniform white suspension. On the day
of dosing, the formulation was removed from refrigera-
tion and administered to dogs at a dosing volume of
4m L / k g .
Blood (approximately 2 mL) was collected via jugular
venipuncture into tubes containing tripotassium ethyl-
enediaminetetraacetic acid (EDTA) anticoagulant before
dosing and at 2, 5, 10, 15, 30, 60, and 90 min and 2, 4, 6,
8, 12, and 24 h after dosing. Blood samples were
maintained on wet ice before centrifugation to obtain
plasma. Centrifugation began within 1 h of sample
collection. Plasma was placed on dry ice before storage
at approximately –70°C.
Plasma samples were analyzed for celecoxib concen-
trations using a liquid chromatography method with
tandem mass spectrometry (LC/MS/MS). In this method,
celecoxib was extracted from dog plasma following protein
precipitation caused by addition of acetonitrile. The drug
peak was isolated by HPLC using a Shimadzu SIL/HT
HPLC instrument (Shimadzu Scientific Instruments, Co-
lumbia, MD) equipped with a Keystone Scientific BDS
Hypersil C8 column (50 mm by 2.0 mm) at 25°C. A
gradient elution using a mixture of 0.02% acetic acid in
water and 0.02% acetic acid in acetonitrile was employed,
with a flow rate of 0.8 mL/min. Multiple-reaction-
monitoring mass spectrometry was used to quantify
celecoxib content using a Sciex 3000 instrument (AB Sciex,
Foster City, CA). The instrument was operated in negative
electrospray mode with an ionization potential of –4500 V,
analyzing for a precursor ion with m/z of 380 and a
product ion with m/z of 316.
In a separate study, performed at Pfizer Inc., 16 beagle
dogs were each given a commercial Celebrex™ capsule
containing 200 mg of celecoxib, for a mean dose of
26.9 mg/kg. The animals were fasted overnight (approxi-
mately 14 h before dosing through approximately 4 h after
dosing). Each dog was weighed on the day of dosing, and
the mean dose was corrected, based on the body weight, to
26.9 mg/kg.
Blood (approximately 2 mL) was collected from the dogs
via jugular venipuncture into tubes containing potassium
EDTA anticoagulant before dosing and at 10, 20, 60, and
90 min and 2, 3, 4, 5, 6, 8, 12, and 24 h after dosing. Blood
samples were maintained on wet ice before centrifugation
to obtain plasma. The resulting plasma samples were
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mately –20°C until analysis.
Plasma samples were analyzed for celecoxib concen-
trations using LC/MS/MS. In this method, celecoxib was
extracted from dog plasma following protein precipitation
caused by addition of buffer and acetonitrile. The drug
peak was isolated by HPLC using a PE Series 200 HPLC
micropump system and autosampler (PerkinElmer,
Waltham, MA) equipped with a Phenomenex phenyl hexyl
5-μm column (50 mm×2.0 mm) at room temperature. A
gradient elution using a mixture of methanol:1.5 mM
ammonium formate and 3.5 mM ammonium hydroxide
(30:70, v/v, Mobile Phase A) and 5 mM ammonium
hydroxide in methanol (Mobile Phase B) was employed at a
flow rate of 0.4 mL/min. Multiple-reaction-monitoring
mass spectrometry was used to quantify celecoxib content
using a Sciex 3000 instrument configured with an
atmospheric-pressure chemical ionization (APCI) source.
The instrument was operated in negative ionization mode
with a turbo ion spray voltage of –5000 V, analyzing for a
precursor ion with m/z of 380, and a product ion with m/z
of 316.
Clinical Pharmacokinetic Study
In the human clinical study, three celecoxib formulations
were assessed: a single 400-mg dose of the marketed
celecoxib capsule (two 200-mg capsules), a single 400-mg
celecoxib dose given as an OPC containing spray-dried
celecoxib nanoparticles, and a single 400-mg celecoxib dose
given as an OPC containing an enteric SDD. Trial
treatments were separated by a washout of at least 7 days.
The Phase 1 open-label, randomized, single-dose
crossover study in 12 healthy adult subjects in the
fasted state was managed by Pfizer Global Research
and Development and conducted by investigators con-
tracted by and under the direction of Pfizer (Study
Protocol A3191216). The study was conducted in
compliance with the ethical principles originating in or
derived from the Declaration of Helsinki and in
compliance with all International Conference on Har-
monization (ICH) Good Clinical Practice (GCP) guide-
lines. In addition, all local regulatory requirements were
followed, in particular, those affording greater protec-
tion to the safety of trial participants.
Clinical study subjects fasted for at least 8 h before
dosing and 4 h after dosing for each treatment period.
Water intake was restricted for 1 h before and after dosing,
except for the volume of water (240 mL/8 fluid ounces)
administered with the celecoxib capsules. The total volume
for subjects receiving suspensions plus water was 240 mL.
Subjects received standardized meals scheduled at the same
time in each period of the study.
Blood samples were collected for analysis of plasma
celecoxib concentrations before dosing and at 15, 30, 45,
60, and 90 min and 2, 3, 4, 6, 8, 12, 24, and 48 h after
dosing. Samples were drawn into tubes containing tripo-
tassium EDTA. The plasma was separated from the whole
blood within approximately 30 min of collection and stored
frozen at approximately –20°C within 60 min of sample
collection. Samples were analyzed using a validated HPLC-
MS/MS method.
Relative Bioavailability
The relative bioavailability—i.e., maximum plasma drug
concentration (Cmax) and area under curve (AUC)—of the
test formulations was assessed and compared with that of
the capsule (control formulation). The log-transformed
Cmax and AUC values were analyzed with a crossover
analysis of variance model that consisted of sequence,
subject within sequence, period, and treatment effects. The
subject within sequence effect was considered random.
Least-squares means and model-based 90% confidence
intervals (CIs) were generated.
RESULTS
Celecoxib:ethyl cellulose:casein nanoparticles were charac-
terized to determine their size, state of matter, release
performance, and resuspendability. Pharmacokinetic tests
were then performed in canine tests and a human clinical
study.
Nanoparticle Size and Shape
The typical nanoparticle diameters measured by DLS were
100 to 150 nm and were unchanged after spray-drying and
resuspension in aqueous media. Nanoparticles were uni-
formly spherical in shape as determined by cryo-TEM
imaging. Figure 1 is a representative cryo-TEM image for
37.5:37.5:25 celecoxib:ethyl cellulose:casein nanoparticles.
Based on DLS analysis of this sample, the nanoparticles
were 128 nm in diameter.
Nanoparticle State of Matter
To assess whether the drug was molecularly dispersed
within the nanoparticle polymer matrix, 37.5:37.5:25
celecoxib:ethyl cellulose:casein nanoparticles were analyzed
by mDSC. Figure 2 is a representative mDSC scan showing
that the nanoparticles have a single distinct Tg of 68°C.
This Tg lies between that of celecoxib (54°C) and that of
the polymer matrix components (ethyl cellulose 126°C,
casein 198°C). No crystals were observed in the nano-
432 Morgen et al.particle suspensions viewed by PLM out to several weeks
after manufacture. PXRD showed no evidence of celecoxib
crystallinity in the spray-dried powders of nanoparticle
suspensions of the composition reported here. The PXRD
pattern in Fig. 3 was taken after storage for 5 years at
ambient conditions.
Release Testing
A nonsink release test was performed to determine the
release rate and the drug activity of the celecoxib nano-
particles. Figure 4 shows the release profiles of nano-
particles with drug loadings of 10%A, 25%A, and 50%A in
MFDS at 40 μg/mL (the NaTC is disregarded when
reporting the loading, since it is believed to be largely in
solution or at the surface of the nanoparticle and not in the
core). The dissolution profile of bulk celecoxib crystals is
shown for comparison. As Fig. 4 shows, the extent of release
from the nanoparticles is a monotonic function of celecoxib
loading, with a higher proportion of the drug releasing at
higher loadings. Release of celecoxib from the nano-
particles is quite rapid, reaching the terminal value within
the first minute. In contrast, the bulk celecoxib crystals take
at least 1 h to reach their maximum concentration in
MFDS (i.e., 16 μg/mL). This maximum concentration is
the sum of dissolved celecoxib plus celecoxib in bile-salt
micelles. As the equilibrium partition coefficient of cele-
coxib into the bile–salt micelles is approximately 1,000 and
the volume of bile–salt micelles in MFDS is about 0.5%,
the dissolved celecoxib concentration at equilibrium is
approximately 2.5 μg/mL, whereas the concentration of
celecoxib in bile–salt micelles is about 13.5 μg/mL.
Figure 5 shows drug activity as a function of drug
loading in the nanoparticle expressed as the ratio of free–
drug concentration provided by the nanoparticle suspen-
sion to crystalline drug solubility. As the figure shows,
depending on the drug loading, the nanoparticles provide
an equilibrium free–drug level that can be either higher or
lower than the crystalline drug solubility.
As shown in Fig. 6, the partition coefficient can be
calculated by fitting a line to the plot of the ratio of
dissolved drug to drug in nanoparticles versus the volume
fraction of ethyl cellulose. This gives an ethyl cellulose/
water partition coefficient for celecoxib of approximately
21,500.
Resuspendability
When spray-dried, the nanoparticles form powders consist-
ing of larger particles 5 to 20 μm in size, each of which is
comprised of numerous nanoparticles. Figure 7 is a SEM of
spray-dried nanoparticles. DLS measurements showed the
particle size of the spray-dried particles when redispersed in
water were similar to the particle size in the initial
suspension (data not shown). To assess whether the spray-
dried particles are likely to resuspend to recover the original
nanoparticles in the gastrointestinal (GI) tract, a resuspen-
sion test was performed with solutions that mimic gastric
and intestinal pH. After transfer of the spray-dried nano-
particles from the simulated gastric to simulated intestinal
medium, the nanoparticles rapidly redispersed.
Figure 8 shows the percentage of drug from resuspended
spray-dried nanoparticles passing through a single 1-μm
filter or sequentially through 1- and 0.45-μm filters. As the
data show, at gastric pH, nearly 100% of the drug from the
resuspended powder (OPC) passes through the 1-μm filter,
whereas little of the drug passes through the 0.45-μm filter.
Nearly all of the drug passing through the filter (>99%) is
Magnification X29000
Fig. 1 Representative cryo-TEM image of a 37.5:37.5:25 celecoxib:ethyl
cellulose:casein nanoparticle suspension at 29,000-fold magnification.
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Polymer Nanoparticles for Improved Bioavailability 433present as nanoparticles, as the dissolved-drug levels in the
simulated gastric medium are <10 μgA/mL (see, for
example, the dissolved-drug levels implied by Fig. 5). At
intestinal pH, nearly 100% of the drug from the resus-
pended powder (OPC) passes through the 1-μm filter and
~80% passes through the 0.45-μm filter.
Pharmacokinetic Studies in Dogs
The pharmacokinetic performance of spray-dried celecoxib
nanoparticles and the commercial celecoxib capsules were
evaluated in a dog model. In the nanoparticle study, six
fasted beagle dogs were each given either a 20-mgA/kg
dose of celecoxib nanoparticles that was prepared and
maintained in a liquid suspension or celecoxib nano-
particles that were spray-dried as an OPC and resuspended
before dosing. In a separate study, 16 dogs were each given
a 200-mg commercial celecoxib capsule, resulting in a
mean dose of 26.9 mgA/kg.
Since the doses in the two dog studies were slightly
different, the systemic exposure data (i.e., Cmax and AUC
data)werenormalizedtothedoseanddog’sbodyweight.The
results are summarized in Table I,a n dp r o f i l e so fm e a n
plasma concentration versus time are presented in Fig. 9.
As shown in Table I, the pharmacokinetic performance
of the two celecoxib nanoparticle formulations is similar.
Thus, the effect of spray-drying and resuspension of the
nanoparticles on in vivo performance is minimal for this
formulation. The bioavailability of the two nanoparticle
formulations—as measured by AUC—was roughly three-
fold higher than that for the commercial capsules. Given
that the bioavailability for the commercial capsules in dogs
is estimated at 25% (17), this translates to roughly 75%
bioavailability for nanoparticles in dogs at this dose.
The Tmax for the nanoparticles is 1.0 to 1.6 h, which is
much shorter than the 3.4 h for the commercial capsules.
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434 Morgen et al.The Cmax for nanoparticles is also substantially higher,
with a roughly four-fold increase relative to the commercial
capsules. Even more importantly, it took only 10 min for
the plasma concentration of the spray-dried nanoparticle
formulation to reach the Cmax of the commercial capsules.
Based on these results, the spray-dried nanoparticles are
expected to provide faster onset of action.
Clinical Pharmacokinetic Study
We describe three formulations used in the clinical pharma-
cokinetic study: the same nanoparticle OPC formulation that
was usedinthe dog studies,an OPC formulation containinga
solid amorphous SDD consisting of 50% celecoxib and 50%
HPMCAS-L (described in the Materials and Methods
section), and the commercial capsule.
Data from the clinical study are presented in Table II
and Fig. 10. In this study, the SDD and nanoparticles had
substantially higher mean Cmax values and somewhat
higher AUC values than the commercial capsules. Specif-
ically, the Cmax values for the nanoparticles and SDD
were roughly 3.1-fold and 2.4-fold those of the commercial
capsules, respectively. The AUC values for the nanoparticle
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commercial capsule, respectively. The rate of absorption for
the nanoparticle formulation was particularly rapid, with a
mean Tmax of 0.75 h, compared with 3.0 h for the
commercial capsules and 2.0 h for the SDD.
DISCUSSION
Physical Characterization of Nanoparticles
As shown by the cryo-TEM image in Fig. 1, the nano-
particles were spherical, which is typical for solid particles
formed using either emulsion or precipitation methods, due
to the favorable energetics associated with minimization of
surface area. The mDSC data, which shows a single Tg
between that of the pure drug and pure ethyl cellulose,
strongly indicates a single phase consisting of celecoxib
molecularly dispersed in ethyl cellulose.
The nonsink release studies were performed in MFDS to
increase the signal-to-noise ratio in the HPLC analysis.
MFDS is also a model for the fasted intestinal environment.
When the nanoparticle suspensions were diluted in MFDS,
the concentration of free drug essentially reached its steady-
state value by the first time point at 1 min. This rapid
dissolution is due to the short diffusion distance of drug
from inside the nanoparticle core to its surface. The rapid
release relative to the bulk crystalline drug (shown in Fig. 4)
is a large part of the reason why the nanoparticles lead to
more rapid absorption of celecoxib.
The release profile, showing that the nanoparticles
release celecoxib rapidly until the concentration of cele-
coxib reaches the equilibrium value, demonstrates that the
celecoxib that remains in the nanoparticles is not kinetically
trapped within the polymeric matrix of the nanoparticle,
but resides within the nanoparticle due to a high thermo-
dynamic solubility. The release data suggest thermodynam-
ic partitioning of the drugb e t w e e nt h ec o r eo ft h e
nanoparticle and the aqueous medium. The partition
coefficient can be calculated by comparing the ratio of
drug in the nanoparticle to drug in the aqueous media at
steady state (reached within 1 min):
Dp
Dfr
¼ KpVp; ð1Þ
where Dp is drug in the nanoparticle, Dfr is the sum of
dissolved drug and drug in bile-salt micelles, Kp is the
polymer/aqueous partition coefficient, and Vp is the volume
fraction of ethyl cellulose in the suspension. Fig. 6 plots the
ratio calculated using Eq. 1 as a function of ethyl cellulose
volume fraction for different drug loadings at equal total
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Fig. 9 Dog pharmacokinetic data for the nanoparticle suspension, resuspended nanoparticles (OPC), and commercial capsule (dose is 200 mgA).
Table I Data from Pharmacokinetic Testing Using a Dog Model
Formulation Dose
(mg/kg)
Dose-Normalized AUC
(hr*ng/ml)/(mg/kg)
Dose-Normalized Cmax
(ng*ml)/(mg/kg)
Tmax (hr) Dogs (n)
200-mgA commercial capsule 26.9 698.3 (413.9) 81.7 (34.3) 3.40 (7.87) 16
Nanoparticle OPC 20.0 1963 (1219) 312.5 (109.7) 1.63 (1.30) 6
Nanoparticle suspension 20.0 2031 (1250) 366.1 (108.1) 1.04 (0.64) 6
436 Morgen et al.drug concentration. The linearity of the plot provides strong
validation of the partitioning model. The partition coefficient
of 21,500 calculated from the slope of the plot suggests a
solubility of celecoxib in ethyl cellulose of approximately
0.30 g/g polymer (assuming an ethyl cellulose density of
1.14 g/mL).
When diluted in an aqueous suspension, celecoxib will
release from the nanoparticle until the drug activities inside
the polymeric nanoparticle and in the aqueous phase are
equal. Physical stability with respect to crystallization of
drug from solution for such nanoparticle aqueous suspen-
sions is a function of the degree of supersaturation of the
aqueous medium, which in turn is a function of drug
activity or loading in the nanoparticles. (Drug activity is
defined as the ratio of solubilized drug provided by the
nanoparticle [C] to the solubility of bulk crystalline drug
[S].) If the drug activity is higher than crystalline, indefinite
physical stability in the liquid state is not to be expected,
due to the driving force for crystallization of dissolved drug.
However, kinetic stability in suspension of many days is
typically observed for formulations with activities 3- to 10-
fold that of crystalline drug. In this case, activity is less than
2, so the nanoparticles could be expected to have good
kinetic stability. Note that the drug/polymer nanoparticles
described here also have excellent physical stability in
suspension with respect to aggregation, due to the use of the
charged surface-active agents.
To produce a solid dosage form such as a tablet or
capsule, drying the nanoparticle suspensions to form a
resuspendable powder is desirable. In addition to making
Table II Pharmacokinetic Data and Relative Bioavailability Comparisons in Humans
Formulation Dose (mg) Adjusted Geometric Means (90% CI in parentheses)
a Ratio
b (90% CI in parentheses)
AUC (hr*ng/ml) Cmax (ng/ml) Tmax (hr) AUC0-tlqc
c Cmax
Commercial capsule
(2×200 mg) (n=11)
400 10,076 (8,965 to 11,371) 799 (667 to 969) 3.0 (1.5 to 4.0) NA
d NA
Nanoparticle OPC
(n=10)
400 13,714 (12,091 to 15,512) 2,487 (2,029 to 3,052) 0.75 (0.75 to 1.0) 136 (120 to 154) 311 (254 to 382)
HPMCAS SDD OPC
(n=12)
400 12,734 (11,285 to 14,308) 1,947 (1,606 to 2,365) 2.0 (1.0 to 4.0) 126 (112 to 142) 244 (201 to 296)
aCI = confidence interval
bRatio of treatment mean values compared to commercial capsule, expressed as a percentage (100%×test/reference)
cAUC0-tlqc = area under the curve from 0 to time of last quantifiable concentration
dNA = not applicable
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Fig. 10 Human pharmacokinetic data for the commercial capsule, resuspended nanoparticles (OPC), and resuspended HPMCAS SDD OPC.
Polymer Nanoparticles for Improved Bioavailability 437processing simpler, this step also typically increases the
storage stability with regard to crystallization. To achieve
rapid absorption due to quick release of drug, the solid
should ideally resuspend quickly and completely into the
original unaggregated, high-surface-area nanoparticles
when exposed to aqueous medium.
To promote this, a water-soluble matrix material, such
as a sugar or hydrophilic polymer, is typically used to
prevent close approach of the nanoparticles, which can lead
to aggregation upon rewetting (22). We have found that
water-soluble amphiphilic polymeric matrix materials are
especially efficient for this purpose, including enteric
polymers in nanoparticles with casein (23) and neutral
polymers in nanoparticles with casein (24). For the
celecoxib nanoparticles described here, a casein matrix
comprising only 20% to 30% of the dry powder resulted in
almost quantitative recovery of the original (unaggregated)
nanoparticles upon resuspension at pH 6.5. The improved
resuspension observed at the typical intestinal pH of 6.5,
relative to typical gastric pH of 2, is likely due to the
carboxy groups on the casein, which become charged at
the higher pH, aiding resuspension through charge-
charge repulsion and increased water solubility. Other
amphiphilic synthetic polymers, such as certain cellulosics
(e.g., carboxymethyl ethyl cellulose [CMEC] and
HPMCAS-L), likewise perform well as resuspension matrix
materials (25).
The powders in this study are made by spray-drying an
aqueous suspension of nanoparticles and dissolved casein.
Spray-drying is a convenient and effective process to
prepare solid powders of nanoparticles. In particular, the
rapid drying kinetics associated with the process helps
prevent irreversible aggregation during drying.
Note that SDDs are not discussed at length in this paper;
they have been described in detail elsewhere (26,27). In
general, SDDs prepared with the enteric polymer
HPMCAS provide excellent total exposure for low-
solubility, lipophilic compounds such as celecoxib (14,28).
The formulation described in this paper has not been
optimized for rapid onset and is referenced only as a
commonly used comparator for this paper.
Pharmacokinetics in Dog and Human
The polymeric nanoparticles described in this study
were studied in the dog and human. In the dog study,
the nanoparticles had a 1:1 celecoxib:ethyl cellulose
ratio, which would be expected to provide free-drug
concentrations of approximately 1.5 times higher than
crystalline drug (as shown in release curve in Fig. 4). All
else being equal, the extent of absorption is proportional
to free-drug concentration. Therefore, part of the increase
in AUC for the nanoparticles relative to the crystalline
drug is likely due to higher dissolved-drug levels for the
nanoparticles. The remainder of the AUC improvement
was likely due to the increased rate of celecoxib release
from the nanoparticles relative to the rate of dissolution of
bulk crystalline celecoxib (Fig. 4). In vivo and in vitro data
show that drying of the nanoparticles followed by
resuspension before dosing had no significant effect on
absorption rate in vivo.
In the human clinical study, administration of 400 mg of
celecoxib as the nanoparticle and the HPMCAS-based
SDD formulations produced higher AUC values than seen
with an equivalent dose of the commercial capsules. The
increase in AUC in humans with the nanoparticles relative
to the commercial capsule was less than that seen in the dog
study. In the studies presented here, absorption was likely
higher in humans than in dogs when celecoxib was dosed as
the capsule, thus limiting the magnitude of absorption
enhancement possible when a nanoparticle formulation is
given. The more complete absorption, particularly with the
nanoparticle formulation, in humans may be related to the
smaller relative dose in humans (3 to 6 mg/kg) versus that in
dogs (20 to 30 mg/kg), as the relative advantage of a
solubilized form increases with dose for low-solubility drugs.
This hypothesis of complete absorption for the nanoparticle
formulation is supported by the fact that the plasma levels,
and therefore absorption, decreases sharply approximately
1 h after the nanoparticles are dosed, whereas absorption
continues for at least 4 h with administration of the
commercial capsules.
T h er a t eo fa b s o r p t i o nf o rt h en a n o p a r t i c l ef o r m u l a -
tion in the clinical study was the fastest of the three
formulations, with a Tmax of 0.75 h. This rapid rate of
absorption for the nanoparticle formulation relative to
the other formulations tested would likely result in a
commensurate decrease in the time to onset of phar-
macological action for the nanoparticle formulation. In
fact, in this study the nanoparticle formulation achieved
plasma concentrations approximately equal to that of
the Cmax for the commercial capsule in only 15 min.
This result can be attributed to the rapid release from
the nanoparticles in the GI tract, allowing rapid free-
drug resupply as drug is absorbed.
The SDD OPC formulation provided similar AUC to
the nanoparticles, but absorption was slower, with a
Tmax of 2.0 h. The longer Tmax may be due to
several factors, including a slower transit time through
the gastric, slower release from the SDD particle, and
lower free-drug levels. The longer Tmax is most likely
partially due to slower drug release from HPMCAS-
based SDDs. Drug release from enteric SDDs in gastric
is often slow, since HPMCAS does not dissolve at
gastric pH. Upon transiting to the higher-pH duode-
num, HPMCAS SDDs dissolve to provide high levels of
438 Morgen et al.dissolved drug and drug/polymer colloids (14). Nano-
particles have higher surface areas and shorter required
drug diffusion distances for release and, thus, readily
source high levels of dissolved drug beginning in the
gastric, and continuing into the duodenum. Note that the
release from the nanoparticles is expected to be faster than
for the SDD, even though the SDD can disintegrate/
dissolve in the higher pH environment of the intestine.
The release rate of the SDD would have likely been slower
if an insoluble polymer, such as the ethyl cellulose used for
the nanoparticles, had been used rather than an enteric
polymer. The differing release characteristics likely ac-
count, in part, for the similar AUC but a longer Tmax
and lower Cmax for the SDD. More work is required to
determine the extent to which differing dissolution rates,
GI transit times, and levels of dissolved drug contribute to
the relatively slower absorption rate for the SDD com-
pared to the nanoparticles.
The nanoparticles described here were dosed as a
suspension rather than as a solid dosage form, which may
have provided a release advantage because no disintegra-
tion of a dosage form was necessary, as it was for the
capsule. In addition, the transit time of small nanoparticles
through the stomach may have been shorter than for the
capsule, which may have led to faster absorption. Based on
previous experience, however, it is likely that a rapidly
disintegrating tablet or capsule can be devised that
maintains the performance advantage that the nanopar-
ticles demonstrated with the OPC formulation. Demon-
stration of this would be part of future work.
CONCLUSIONS
The feasibility of using drug/polymer nanoparticles to
improve oral bioavailability and achieve rapid absorption
was demonstrated by incorporating celecoxib as a model
compound within ethyl cellulose/casein nanoparticles.
These nanoparticles, which had diameters of 100 to
150 nm, were prepared using an emulsion process. The
nanoparticles consisted of a single amorphous phase of drug
dispersed within the ethyl cellulose matrix, in which the
drug has appreciable solubility (0.30 g/g polymer). Drug
release from the particles was rapid, reaching its equilibri-
um value in the dissolution medium within 1 min. At high
drug loading, the nanoparticles provided dissolved-drug
levels higher than crystalline solubility. The nanoparticle
suspensions were stable for several days and can be spray-
dried to form a dry powder that resuspends in water to
yield the original unaggregated nanoparticles.
The nanoparticles provided higher total celecoxib
exposure and faster absorption in dogs and humans than
commercial capsules. In humans, the celecoxib Tmax was
0.75 h for the nanoparticle formulation versus 3 h for the
commercial capsules.
Based on the results presented here, drug/polymer nano-
particles can provide higher bioavailability than micronized
crystals of BCS Class II compounds. In addition, they can
provide more rapid absorption and, therefore, potentially
more rapid onset of action, than either micronized crystals or
slower dissolving amorphous drug forms of BCS Class II
compounds. The nanoparticles described here are also
amenable to preparation as a solid dosage form.
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